FDA approves Zepatier for treatment of chronic hepatitis C genotypes 1 and 4
FDA News Release For Immediate Release January 28, 2016 Release The U.S. Food and Drug Administration today approved Zepatier (elbasvir and grazoprevir) with or without ribavirin for the treatment of chronic hepatitis C virus (HCV) genotypes 1 and 4 infections in adult patients. Hepatitis C